ReviewExpert opinion on drug delivery2021
Enhancing nanoparticle penetration through airway mucus to improve drug delivery efficacy in the lung.
Review in Expert opinion on drug delivery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 86 citations in OpenAlex.
- Solid Lipid Nanoparticles Based Dry Powder Inhalers for Enhanced Drug Delivery Against Lung Diseases.AAPS PharmSciTech · 2026Review
- Fabrication of Budesonide-Encapsulated β-Glucan Nanoparticles for Alleviation of Acute Bronchial Asthma via Modulation of the p38 MAPK Signaling Pathway.Applied biochemistry and biotechnology · 2026Article
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Microfluidic Production and Characterisation of Cyclosporine A-Loaded Lipid-Chitosan Hybrid Nanoparticles as Candidate Pulmonary Drug Delivery Systems.Pharmaceutics · 2026Article
- Epithelial-immune interface in asthma: Mechanistic insights driving novel therapeutic strategies.Seminars in immunopathology · 2026Review
- Pulmonary Drug Delivery in the Era of Nanomedicine: From Biological Barriers to Artificial Intelligence-Driven Optimization.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Remodeling the pathological airway: advanced nanotechnology for diagnostics and therapeutics in cystic fibrosis.Journal of nanobiotechnology · 2026Review
- Lung surfactants as a component of lipid nanoparticles for pulmonary mRNA delivery.bioRxiv : the preprint server for biology · 2026Article
- Mucoactive Agents in Muco-Obstructive Lung Diseases: A Critical Reappraisal of Pharmacological Effects and Clinical Outcomes.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Inhalation-Based Nanoparticle Drug Delivery Targeting the Diseased Lower Airways in Idiopathic Pulmonary Fibrosis.Pharmaceutics · 2026Review
- Advancements in Nanoparticle-Based Therapies for Breast Cancer: Current Trends and Future Prospects.International journal of breast cancer · 2026Review
- Inhalable Nanosystems for Bacterial Respiratory Infections: Addressing Pulmonary Barriers and Biofilm-Associated Challenges.International journal of nanomedicine · 2026Review
- Inhalable nanoparticle-based delivery systems for the treatment of pulmonary infections:Drug delivery · 2025Review
- Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives.Pharmaceutics · 2025Review
- Tailored Levofloxacin Incorporated Extracellular Matrix Nanoparticles for Pulmonary Infections.International journal of molecular sciences · 2025Article
- Inflammatory lung diseases: a clinical and scientific review of the latest advances and challenges.Pharmacological reports : PR · 2025Review
- Inhalable Nanomaterial Discoveries for Lung Cancer Therapy: A Review.Pharmaceutics · 2025Review
- RNA lipid nanoparticles stabilized during nebulization through excipient selection.Nanoscale advances · 2025Article
- Exploring the Potential of PLGA Nanoparticles for Enhancing Pulmonary Drug Delivery.Molecular pharmaceutics · 2025Review
- Silicon Carbide Nanowires Impair Mucociliary Clearance-Mediated Innate Immunity in Primary Human Bronchial Epithelial Cells.ACS nano · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.